Lenalidomide
Luspatercept reduces transfusion burden for certain patients with lower-risk myelodysplastic syndrome
Novel therapy combination effective in large cell lymphoma
Lenalidomide plus obinutuzumab effective in relapsed low-grade lymphoma
Polatuzumab vedotin plus obinutuzumab, lenalidomide shows promise in R/R follicular lymphoma
ORLANDO — Catherine Diefenbach, MD, director of the clinical lymphoma program and of hematology translational research, Perlmutter Cancer Center at NYU Langone Health, presented efficacy and safety data from a phase 1b/2 study of polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed/refractory follicular lymphoma at ASH Annual Meeting & Exposition.
Daratumumab regimen increases response in transplant-eligible multiple myeloma
ORLANDO — The addition of daratumumab to lenalidomide, bortezomib and dexamethasone significantly improved rates of stringent clinical response and minimal disease negativity among patients with transplant-eligible newly diagnosed multiple myeloma, according to results of the randomized phase 2 GRIFFIN study presented at ASH Annual Meeting and Exposition.
Three-agent regimen effective, safe in high-risk smoldering multiple myeloma
Triplet therapy active in diffuse large B-cell lymphoma
The combination of ibrutinib, lenalidomide and rituximab demonstrated robust, ongoing activity among patients with relapsed or refractory diffuse large B-cell lymphoma, especially those with nongerminal center B-cell DLBCL, according to results of the dose-escalation portion of a phase 1b/phase 2 study published in Blood.